nodes	percent_of_prediction	percent_of_DWPC	metapath
Levomilnacipran—Yawning—Riluzole—amyotrophic lateral sclerosis	0.0457	0.0549	CcSEcCtD
Levomilnacipran—Supraventricular tachycardia—Riluzole—amyotrophic lateral sclerosis	0.0281	0.0338	CcSEcCtD
Levomilnacipran—Mania—Riluzole—amyotrophic lateral sclerosis	0.0253	0.0304	CcSEcCtD
Levomilnacipran—Extrapyramidal disorder—Riluzole—amyotrophic lateral sclerosis	0.0244	0.0294	CcSEcCtD
Levomilnacipran—Endocrine disorder—Riluzole—amyotrophic lateral sclerosis	0.0222	0.0267	CcSEcCtD
Levomilnacipran—Delirium—Riluzole—amyotrophic lateral sclerosis	0.0214	0.0257	CcSEcCtD
Levomilnacipran—Ventricular extrasystoles—Riluzole—amyotrophic lateral sclerosis	0.0204	0.0245	CcSEcCtD
Levomilnacipran—Hypercholesterolaemia—Riluzole—amyotrophic lateral sclerosis	0.0194	0.0234	CcSEcCtD
Levomilnacipran—Libido decreased—Riluzole—amyotrophic lateral sclerosis	0.0144	0.0173	CcSEcCtD
Levomilnacipran—Thirst—Riluzole—amyotrophic lateral sclerosis	0.014	0.0169	CcSEcCtD
Levomilnacipran—Hyponatraemia—Riluzole—amyotrophic lateral sclerosis	0.0134	0.0161	CcSEcCtD
Levomilnacipran—Disturbance in sexual arousal—Riluzole—amyotrophic lateral sclerosis	0.0132	0.0159	CcSEcCtD
Levomilnacipran—Migraine—Riluzole—amyotrophic lateral sclerosis	0.0131	0.0158	CcSEcCtD
Levomilnacipran—Urinary retention—Riluzole—amyotrophic lateral sclerosis	0.0127	0.0153	CcSEcCtD
Levomilnacipran—Liver function test abnormal—Riluzole—amyotrophic lateral sclerosis	0.0123	0.0148	CcSEcCtD
Levomilnacipran—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.0121	0.0145	CcSEcCtD
Levomilnacipran—CYP2J2—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—amyotrophic lateral sclerosis	0.0116	0.106	CbGpPWpGaD
Levomilnacipran—Abdominal distension—Riluzole—amyotrophic lateral sclerosis	0.0116	0.014	CcSEcCtD
Levomilnacipran—Angina pectoris—Riluzole—amyotrophic lateral sclerosis	0.0112	0.0135	CcSEcCtD
Levomilnacipran—Dysuria—Riluzole—amyotrophic lateral sclerosis	0.0108	0.013	CcSEcCtD
Levomilnacipran—Neutropenia—Riluzole—amyotrophic lateral sclerosis	0.0108	0.013	CcSEcCtD
Levomilnacipran—Pollakiuria—Riluzole—amyotrophic lateral sclerosis	0.0107	0.0128	CcSEcCtD
Levomilnacipran—SLC6A4—Synaptic Vesicle Pathway—UNC13A—amyotrophic lateral sclerosis	0.0107	0.0973	CbGpPWpGaD
Levomilnacipran—Erectile dysfunction—Riluzole—amyotrophic lateral sclerosis	0.0106	0.0128	CcSEcCtD
Levomilnacipran—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.0104	0.0126	CcSEcCtD
Levomilnacipran—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.01	0.012	CcSEcCtD
Levomilnacipran—Haematuria—Riluzole—amyotrophic lateral sclerosis	0.00981	0.0118	CcSEcCtD
Levomilnacipran—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.00973	0.0117	CcSEcCtD
Levomilnacipran—Hepatitis—Riluzole—amyotrophic lateral sclerosis	0.00923	0.0111	CcSEcCtD
Levomilnacipran—Hypoaesthesia—Riluzole—amyotrophic lateral sclerosis	0.00919	0.0111	CcSEcCtD
Levomilnacipran—Hallucination—Riluzole—amyotrophic lateral sclerosis	0.00919	0.0111	CcSEcCtD
Levomilnacipran—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.00912	0.011	CcSEcCtD
Levomilnacipran—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.0091	0.0109	CcSEcCtD
Levomilnacipran—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.00907	0.0109	CcSEcCtD
Levomilnacipran—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.00905	0.0109	CcSEcCtD
Levomilnacipran—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.00873	0.0105	CcSEcCtD
Levomilnacipran—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.00863	0.0104	CcSEcCtD
Levomilnacipran—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.00857	0.0103	CcSEcCtD
Levomilnacipran—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.00838	0.0101	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00832	0.01	CcSEcCtD
Levomilnacipran—Chills—Riluzole—amyotrophic lateral sclerosis	0.00829	0.00997	CcSEcCtD
Levomilnacipran—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.00809	0.00974	CcSEcCtD
Levomilnacipran—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.00804	0.00967	CcSEcCtD
Levomilnacipran—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.00792	0.00953	CcSEcCtD
Levomilnacipran—Tension—Riluzole—amyotrophic lateral sclerosis	0.00789	0.00949	CcSEcCtD
Levomilnacipran—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.00787	0.00947	CcSEcCtD
Levomilnacipran—Tremor—Riluzole—amyotrophic lateral sclerosis	0.00753	0.00906	CcSEcCtD
Levomilnacipran—Agitation—Riluzole—amyotrophic lateral sclerosis	0.00739	0.00889	CcSEcCtD
Levomilnacipran—Syncope—Riluzole—amyotrophic lateral sclerosis	0.00721	0.00868	CcSEcCtD
Levomilnacipran—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.0072	0.00866	CcSEcCtD
Levomilnacipran—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.0071	0.00855	CcSEcCtD
Levomilnacipran—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00707	0.0085	CcSEcCtD
Levomilnacipran—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.00697	0.00838	CcSEcCtD
Levomilnacipran—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.00694	0.00835	CcSEcCtD
Levomilnacipran—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.00684	0.00824	CcSEcCtD
Levomilnacipran—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.00682	0.00821	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.0068	0.00818	CcSEcCtD
Levomilnacipran—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.00669	0.00806	CcSEcCtD
Levomilnacipran—Infection—Riluzole—amyotrophic lateral sclerosis	0.00652	0.00784	CcSEcCtD
Levomilnacipran—Shock—Riluzole—amyotrophic lateral sclerosis	0.00645	0.00777	CcSEcCtD
Levomilnacipran—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.00643	0.00774	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.00642	0.00773	CcSEcCtD
Levomilnacipran—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.0064	0.00771	CcSEcCtD
Levomilnacipran—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.00637	0.00767	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.00634	0.00763	CcSEcCtD
Levomilnacipran—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.00625	0.00753	CcSEcCtD
Levomilnacipran—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.00613	0.00738	CcSEcCtD
Levomilnacipran—SLC6A2—nerve—amyotrophic lateral sclerosis	0.00607	0.102	CbGeAlD
Levomilnacipran—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.00593	0.00714	CcSEcCtD
Levomilnacipran—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.00589	0.00709	CcSEcCtD
Levomilnacipran—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.00585	0.00704	CcSEcCtD
Levomilnacipran—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.00583	0.00702	CcSEcCtD
Levomilnacipran—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.00578	0.00695	CcSEcCtD
Levomilnacipran—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.0057	0.00686	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00566	0.00682	CcSEcCtD
Levomilnacipran—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.00566	0.00681	CcSEcCtD
Levomilnacipran—Constipation—Riluzole—amyotrophic lateral sclerosis	0.00561	0.00675	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.00537	0.00646	CcSEcCtD
Levomilnacipran—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.00521	0.00627	CcSEcCtD
Levomilnacipran—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.00519	0.00624	CcSEcCtD
Levomilnacipran—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.00519	0.00624	CcSEcCtD
Levomilnacipran—SLC6A4—hindbrain—amyotrophic lateral sclerosis	0.00516	0.0866	CbGeAlD
Levomilnacipran—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.00483	0.00582	CcSEcCtD
Levomilnacipran—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.00471	0.00567	CcSEcCtD
Levomilnacipran—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.00464	0.00559	CcSEcCtD
Levomilnacipran—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00449	0.0054	CcSEcCtD
Levomilnacipran—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.00434	0.00522	CcSEcCtD
Levomilnacipran—SLC6A2—Na+/Cl- dependent neurotransmitter transporters—SLC6A1—amyotrophic lateral sclerosis	0.00429	0.0392	CbGpPWpGaD
Levomilnacipran—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.00417	0.00502	CcSEcCtD
Levomilnacipran—Rash—Riluzole—amyotrophic lateral sclerosis	0.00414	0.00498	CcSEcCtD
Levomilnacipran—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00413	0.00497	CcSEcCtD
Levomilnacipran—Headache—Riluzole—amyotrophic lateral sclerosis	0.00411	0.00495	CcSEcCtD
Levomilnacipran—Nausea—Riluzole—amyotrophic lateral sclerosis	0.0039	0.00469	CcSEcCtD
Levomilnacipran—CYP2J2—medulla oblongata—amyotrophic lateral sclerosis	0.00383	0.0642	CbGeAlD
Levomilnacipran—CYP2J2—spinal cord—amyotrophic lateral sclerosis	0.00341	0.0572	CbGeAlD
Levomilnacipran—SLC6A4—Monoamine Transport—SLC6A1—amyotrophic lateral sclerosis	0.00329	0.03	CbGpPWpGaD
Levomilnacipran—SLC6A2—Amine compound SLC transporters—SLC6A1—amyotrophic lateral sclerosis	0.00298	0.0272	CbGpPWpGaD
Levomilnacipran—SLC6A4—brainstem—amyotrophic lateral sclerosis	0.00296	0.0496	CbGeAlD
Levomilnacipran—CYP2C8—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—amyotrophic lateral sclerosis	0.00291	0.0266	CbGpPWpGaD
Levomilnacipran—CYP2J2—nervous system—amyotrophic lateral sclerosis	0.00288	0.0482	CbGeAlD
Levomilnacipran—SLC6A2—Monoamine Transport—SLC6A1—amyotrophic lateral sclerosis	0.00283	0.0258	CbGpPWpGaD
Levomilnacipran—CYP2J2—central nervous system—amyotrophic lateral sclerosis	0.00277	0.0464	CbGeAlD
Levomilnacipran—CYP2J2—cerebellum—amyotrophic lateral sclerosis	0.00271	0.0454	CbGeAlD
Levomilnacipran—SLC6A4—Circadian rythm related genes—SETX—amyotrophic lateral sclerosis	0.00269	0.0246	CbGpPWpGaD
Levomilnacipran—SLC6A2—brainstem—amyotrophic lateral sclerosis	0.00261	0.0437	CbGeAlD
Levomilnacipran—SLC6A4—Synaptic Vesicle Pathway—SLC1A3—amyotrophic lateral sclerosis	0.00254	0.0232	CbGpPWpGaD
Levomilnacipran—CYP2D6—hindbrain—amyotrophic lateral sclerosis	0.00249	0.0417	CbGeAlD
Levomilnacipran—CYP2C19—Melatonin metabolism and effects—ECE1—amyotrophic lateral sclerosis	0.0024	0.022	CbGpPWpGaD
Levomilnacipran—CYP2J2—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.00222	0.0203	CbGpPWpGaD
Levomilnacipran—CYP2D6—Melatonin metabolism and effects—ECE1—amyotrophic lateral sclerosis	0.00221	0.0202	CbGpPWpGaD
Levomilnacipran—CYP2J2—brain—amyotrophic lateral sclerosis	0.0022	0.0369	CbGeAlD
Levomilnacipran—CYP2J2—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.00201	0.0184	CbGpPWpGaD
Levomilnacipran—SLC6A4—spinal cord—amyotrophic lateral sclerosis	0.00184	0.0309	CbGeAlD
Levomilnacipran—SLC6A2—medulla oblongata—amyotrophic lateral sclerosis	0.00182	0.0305	CbGeAlD
Levomilnacipran—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—amyotrophic lateral sclerosis	0.00168	0.0154	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—ECE1—amyotrophic lateral sclerosis	0.00161	0.0147	CbGpPWpGaD
Levomilnacipran—SLC6A4—nervous system—amyotrophic lateral sclerosis	0.00155	0.026	CbGeAlD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.00155	0.0141	CbGpPWpGaD
Levomilnacipran—SLC6A4—central nervous system—amyotrophic lateral sclerosis	0.00149	0.025	CbGeAlD
Levomilnacipran—CYP2D6—brainstem—amyotrophic lateral sclerosis	0.00143	0.0239	CbGeAlD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.00141	0.0129	CbGpPWpGaD
Levomilnacipran—SLC6A2—nervous system—amyotrophic lateral sclerosis	0.00136	0.0229	CbGeAlD
Levomilnacipran—SLC6A4—NRF2 pathway—GSR—amyotrophic lateral sclerosis	0.00133	0.0122	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.00131	0.012	CbGpPWpGaD
Levomilnacipran—SLC6A2—central nervous system—amyotrophic lateral sclerosis	0.00131	0.022	CbGeAlD
Levomilnacipran—CYP2J2—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	0.00125	0.0114	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.00124	0.0113	CbGpPWpGaD
Levomilnacipran—SLC6A4—brain—amyotrophic lateral sclerosis	0.00118	0.0199	CbGeAlD
Levomilnacipran—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A1—amyotrophic lateral sclerosis	0.00116	0.0106	CbGpPWpGaD
Levomilnacipran—SLC6A2—NRF2 pathway—GSR—amyotrophic lateral sclerosis	0.00115	0.0105	CbGpPWpGaD
Levomilnacipran—ABCB1—embryo—amyotrophic lateral sclerosis	0.00112	0.0188	CbGeAlD
Levomilnacipran—SLC6A2—brain—amyotrophic lateral sclerosis	0.00104	0.0175	CbGeAlD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—CHAT—amyotrophic lateral sclerosis	0.00104	0.00949	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—AQP4—amyotrophic lateral sclerosis	0.00104	0.00949	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—SLC1A3—amyotrophic lateral sclerosis	0.00104	0.00949	CbGpPWpGaD
Levomilnacipran—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—amyotrophic lateral sclerosis	0.00104	0.00948	CbGpPWpGaD
Levomilnacipran—SLC6A4—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	0.000976	0.00892	CbGpPWpGaD
Levomilnacipran—CYP2J2—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000899	0.00821	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000886	0.0081	CbGpPWpGaD
Levomilnacipran—CYP2C8—brain—amyotrophic lateral sclerosis	0.000857	0.0144	CbGeAlD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.000847	0.00774	CbGpPWpGaD
Levomilnacipran—SLC6A2—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	0.000839	0.00767	CbGpPWpGaD
Levomilnacipran—CYP3A4—nervous system—amyotrophic lateral sclerosis	0.000759	0.0127	CbGeAlD
Levomilnacipran—SLC6A4—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.000752	0.00688	CbGpPWpGaD
Levomilnacipran—CYP2D6—nervous system—amyotrophic lateral sclerosis	0.000747	0.0125	CbGeAlD
Levomilnacipran—CYP3A4—central nervous system—amyotrophic lateral sclerosis	0.000731	0.0123	CbGeAlD
Levomilnacipran—CYP2D6—central nervous system—amyotrophic lateral sclerosis	0.000719	0.0121	CbGeAlD
Levomilnacipran—SLC6A4—Circadian rythm related genes—CST3—amyotrophic lateral sclerosis	0.000716	0.00654	CbGpPWpGaD
Levomilnacipran—ABCB1—medulla oblongata—amyotrophic lateral sclerosis	0.000715	0.012	CbGeAlD
Levomilnacipran—CYP2D6—cerebellum—amyotrophic lateral sclerosis	0.000703	0.0118	CbGeAlD
Levomilnacipran—SLC6A2—SLC-mediated transmembrane transport—SLC1A2—amyotrophic lateral sclerosis	0.000698	0.00638	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000689	0.00629	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000689	0.00629	CbGpPWpGaD
Levomilnacipran—SLC6A2—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.000647	0.00591	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	0.000642	0.00587	CbGpPWpGaD
Levomilnacipran—ABCB1—spinal cord—amyotrophic lateral sclerosis	0.000638	0.0107	CbGeAlD
Levomilnacipran—CYP2J2—Metabolism—VAPA—amyotrophic lateral sclerosis	0.00063	0.00576	CbGpPWpGaD
Levomilnacipran—CYP2C19—Melatonin metabolism and effects—APOE—amyotrophic lateral sclerosis	0.000629	0.00575	CbGpPWpGaD
Levomilnacipran—SLC6A2—SLC-mediated transmembrane transport—SLC1A3—amyotrophic lateral sclerosis	0.000593	0.00542	CbGpPWpGaD
Levomilnacipran—SLC6A4—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.000589	0.00538	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000586	0.00535	CbGpPWpGaD
Levomilnacipran—CYP2D6—Melatonin metabolism and effects—APOE—amyotrophic lateral sclerosis	0.000579	0.00529	CbGpPWpGaD
Levomilnacipran—CYP2D6—brain—amyotrophic lateral sclerosis	0.000571	0.00958	CbGeAlD
Levomilnacipran—CYP2C8—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000554	0.00506	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000551	0.00503	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.00055	0.00503	CbGpPWpGaD
Levomilnacipran—ABCB1—nervous system—amyotrophic lateral sclerosis	0.000538	0.00902	CbGeAlD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—BDNF—amyotrophic lateral sclerosis	0.000537	0.00491	CbGpPWpGaD
Levomilnacipran—SLC6A2—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	0.000529	0.00483	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—CASP12—amyotrophic lateral sclerosis	0.000519	0.00474	CbGpPWpGaD
Levomilnacipran—ABCB1—central nervous system—amyotrophic lateral sclerosis	0.000518	0.00868	CbGeAlD
Levomilnacipran—SLC6A2—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.000506	0.00462	CbGpPWpGaD
Levomilnacipran—ABCB1—cerebellum—amyotrophic lateral sclerosis	0.000506	0.00848	CbGeAlD
Levomilnacipran—CYP2C8—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000501	0.00458	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—DAO—amyotrophic lateral sclerosis	0.000498	0.00455	CbGpPWpGaD
Levomilnacipran—CYP2C19—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000494	0.00452	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000448	0.00409	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—RARA—amyotrophic lateral sclerosis	0.000423	0.00387	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—CASP9—amyotrophic lateral sclerosis	0.000416	0.0038	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000412	0.00376	CbGpPWpGaD
Levomilnacipran—ABCB1—brain—amyotrophic lateral sclerosis	0.000411	0.00689	CbGeAlD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000386	0.00353	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000377	0.00345	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000355	0.00324	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000353	0.00323	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—GSR—amyotrophic lateral sclerosis	0.000348	0.00318	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000345	0.00315	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—CD40LG—amyotrophic lateral sclerosis	0.000335	0.00306	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.000328	0.003	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	0.000317	0.0029	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000315	0.00288	CbGpPWpGaD
Levomilnacipran—CYP2C8—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	0.000312	0.00285	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.000309	0.00282	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000302	0.00276	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000302	0.00276	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—C3—amyotrophic lateral sclerosis	0.000296	0.0027	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.000293	0.00268	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—MAPT—amyotrophic lateral sclerosis	0.000291	0.00266	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000286	0.00261	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—CST3—amyotrophic lateral sclerosis	0.000282	0.00258	CbGpPWpGaD
Levomilnacipran—CYP2C19—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	0.000279	0.00255	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.000275	0.00252	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000269	0.00246	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000269	0.00246	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	0.000268	0.00245	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—IGFBP3—amyotrophic lateral sclerosis	0.000266	0.00243	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	0.000261	0.00238	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000242	0.00221	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	0.000228	0.00208	CbGpPWpGaD
Levomilnacipran—CYP2C8—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000224	0.00205	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000221	0.00202	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.000212	0.00193	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	0.000205	0.00188	CbGpPWpGaD
Levomilnacipran—CYP2C19—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.0002	0.00183	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000198	0.0018	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.000189	0.00173	CbGpPWpGaD
Levomilnacipran—CYP2D6—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000184	0.00168	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000182	0.00166	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	0.000179	0.00163	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—CASP3—amyotrophic lateral sclerosis	0.000175	0.0016	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	0.000173	0.00158	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000172	0.00157	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000172	0.00157	CbGpPWpGaD
Levomilnacipran—ABCB1—HIF-1-alpha transcription factor network—VEGFA—amyotrophic lateral sclerosis	0.000172	0.00157	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	0.000165	0.00151	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	0.00016	0.00146	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000157	0.00144	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000156	0.00143	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—GSTP1—amyotrophic lateral sclerosis	0.000154	0.0014	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000153	0.0014	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000153	0.0014	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—VAPB—amyotrophic lateral sclerosis	0.00015	0.00137	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—TPK1—amyotrophic lateral sclerosis	0.00015	0.00137	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—VEGFA—amyotrophic lateral sclerosis	0.000149	0.00136	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000146	0.00134	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	0.000143	0.00131	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000141	0.00129	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000141	0.00129	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000141	0.00129	CbGpPWpGaD
Levomilnacipran—SLC6A4—Circadian rythm related genes—TP53—amyotrophic lateral sclerosis	0.000141	0.00128	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—VAPA—amyotrophic lateral sclerosis	0.00014	0.00128	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000137	0.00126	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000137	0.00125	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000133	0.00121	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000133	0.00121	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.00013	0.00119	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000129	0.00118	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000127	0.00116	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—DAO—amyotrophic lateral sclerosis	0.000124	0.00114	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000123	0.00112	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.00012	0.0011	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.00012	0.0011	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—FIG4—amyotrophic lateral sclerosis	0.00012	0.00109	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000119	0.00109	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000118	0.00108	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—APOE—amyotrophic lateral sclerosis	0.000116	0.00106	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000113	0.00103	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	0.000112	0.00103	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—DAO—amyotrophic lateral sclerosis	0.000111	0.00101	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—DAO—amyotrophic lateral sclerosis	0.000108	0.00099	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—DAO—amyotrophic lateral sclerosis	0.000102	0.000933	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PLB1—amyotrophic lateral sclerosis	9.42e-05	0.000861	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	9.31e-05	0.000851	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	9.23e-05	0.000843	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	9.23e-05	0.000843	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GSR—amyotrophic lateral sclerosis	8.69e-05	0.000794	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	8.64e-05	0.00079	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	8.44e-05	0.000771	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PLB1—amyotrophic lateral sclerosis	8.41e-05	0.000768	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PLB1—amyotrophic lateral sclerosis	8.21e-05	0.00075	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PTGS2—amyotrophic lateral sclerosis	7.96e-05	0.000728	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	7.92e-05	0.000724	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	7.85e-05	0.000717	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GSR—amyotrophic lateral sclerosis	7.76e-05	0.000709	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PLB1—amyotrophic lateral sclerosis	7.73e-05	0.000707	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GSR—amyotrophic lateral sclerosis	7.57e-05	0.000692	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	7.38e-05	0.000674	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	7.34e-05	0.00067	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CHAT—amyotrophic lateral sclerosis	7.14e-05	0.000652	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GSR—amyotrophic lateral sclerosis	7.14e-05	0.000652	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	7.07e-05	0.000646	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	6.67e-05	0.00061	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	6.51e-05	0.000595	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CHAT—amyotrophic lateral sclerosis	6.37e-05	0.000582	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CHAT—amyotrophic lateral sclerosis	6.22e-05	0.000568	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CHAT—amyotrophic lateral sclerosis	5.86e-05	0.000536	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	5.81e-05	0.000531	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	5.54e-05	0.000507	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	5.06e-05	0.000462	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	4.67e-05	0.000426	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	4.46e-05	0.000408	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	3.98e-05	0.000364	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.84e-05	0.000351	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	3.83e-05	0.00035	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.53e-05	0.000322	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.42e-05	0.000313	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.34e-05	0.000305	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.15e-05	0.000288	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.15e-05	0.000288	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.07e-05	0.000281	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—APOE—amyotrophic lateral sclerosis	2.9e-05	0.000265	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.89e-05	0.000265	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—APOE—amyotrophic lateral sclerosis	2.59e-05	0.000237	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—APOE—amyotrophic lateral sclerosis	2.53e-05	0.000231	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—APOE—amyotrophic lateral sclerosis	2.38e-05	0.000218	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.06e-05	0.000188	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.99e-05	0.000182	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.89e-05	0.000173	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.77e-05	0.000162	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.73e-05	0.000158	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.63e-05	0.000149	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	1.56e-05	0.000142	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.07e-05	9.75e-05	CbGpPWpGaD
